Related Experiment Video
Updated: Jul 14, 2026

Analysis of HBV-Specific CD4 T-cell Responses and Identification of HLA-DR-Restricted CD4 T-Cell Epitopes Based on a Peptide Matrix
Published on: October 20, 2021
Proteasomal degradation of core protein variants from chronic hepatitis B patients
Sabine Braun1, Anna Zajakina, Jekaterina Aleksejeva
1Universitätsmedizin Berlin, Charité, Institut für Virologie, Campus Mitte, Charitéplatz 1, Berlin, Germany.
Insights
Hepatitis B virus (HBV) variants with C gene deletions in transplant patients show lower core protein levels and faster degradation. This proteasomal pathway involvement impacts HBV infection severity and end-stage liver disease progression.
Area of Science:
- Virology
- Immunology
- Hepatology
Background:
- Hepatitis B virus (HBV) variants with internal C gene deletions are linked to severe infections and end-stage liver disease (ESLD) in immunosuppressed renal transplant recipients.
- Understanding the behavior of these HBV variants is crucial for managing infection in vulnerable patient populations.
Purpose of the Study:
- To investigate the synthesis and proteasomal degradation of HBV core (HBc) protein variants with internal in-frame deletions.
- To compare the stability and turnover of these deletion variants with wild-type HBc protein.
Main Methods:
- Expression of six HBV C genes with internal in-frame deletions in two eukaryotic cell lines.
- Comparison of steady-state levels and proteasomal degradation rates of wild-type HBc and deletion variant HBc proteins.
Main Results:
- Internally deleted HBc proteins, especially those with longer deletions, exhibited considerably lower steady-state levels compared to wild-type HBc.
- Deletion variants demonstrated significantly higher turnover rates, being rapidly degraded via the proteasome pathway.
Conclusions:
- Proteasomal degradation plays a significant role in the turnover of HBc protein variants with internal deletions.
- The rapid degradation of these variants may influence the clinical course of HBV infection in immunosuppressed patients.
Abstract:
The accumulation of complex hepatitis B virus (HBV) variants with internal in-frame deletions in the C gene in immunosuppressed renal transplant recipients is associated with a severe course of the infection leading to end-stage liver disease (ESLD). A set of six HBV C genes with internal in-frame deletions corresponding to the pattern of HBV population in immunosuppressed patients has been expressed in two different eukaryotic cell lines. Synthesis and proteasomal degradation of HBV core (HBc) protein variants were compared with those of the wild-type HBc. In all cases, the steady-state level of internally deleted HBc proteins, predominantly with longer deletions, were considerably lower and turnover was significantly higher in comparison with those of the wild-type HBc, since all deletion variants were degraded rapidly via the proteasome pathway. Involvement and consequences of the proteasomal degradation machinery in the HBc protein turnover during HBV infection with complex HBV variants in the immunosuppressed patients are discussed.
More Related Videos
Related Concept Videos
The Proteasome
In this pathway, the target proteins are first tagged with small proteins called ubiquitin. This involves participation of a series of enzymes including— E1 (ubiquitin-activating enzyme), E2 (ubiquitin-conjugating enzyme), and E3 (ubiquitin...
The Proteasome
In this pathway, the target proteins are first tagged with small proteins called ubiquitin. A series of enzymes carry out the ubiquitination of the target proteins - E1 (ubiquitin-activating enzyme), E2 (ubiquitin-conjugating enzyme), and E3...
The Proteasome
In this pathway, the target proteins are first tagged with small proteins called ubiquitin. A series of enzymes carry out the ubiquitination of the target proteins - E1 (ubiquitin-activating enzyme), E2 (ubiquitin-conjugating enzyme), and E3...
Hepatitis
Viral Hepatitis I: Introduction
Hepatic Drug Clearance: Effect of Protein Binding
For low-extraction-ratio drugs that are less than 80% protein-bound, minor changes in protein binding...

